Prostate Cancer: Dissatisfaction With Current Diagnostics Drives Interest In Innovation
This article was originally published in Start Up
Executive Summary
The lack of accurate tools for diagnosing the severity of prostate cancer creates opportunities for start-ups with novel approaches. Profiles of 3D Biopsy, Blue Earth Diagnostics, UroSens, and Prostate Management Diagnostics.
You may also be interested in...
Genetic Biomarkers Offer New Hope In Identifying Prostate Cancer
Although physicians still struggle with the best ways to treat patients suspected of having prostate cancer, a new group of genetic-based tests could provide new tools that will help improve diagnostic accuracy. These new biomarkers offer hope in reducing the number of patients who receive unnecessary treatment for cancers that are not actually present in their bodies and for those cancers not aggressive enough to cause harm.
3DBiopsy LLC
3DBiopsy LLC thinks its technology could significantly improve a physician’s ability to diagnose and treat patients suspected of having prostate cancer. It has developed a complete biopsy system that utilizes the start-up’s proprietary software to transform ultrasound or MRI imaging into 3D models of the prostate and give physicians a more accurate guide.
UroSens Ltd.
UroSens Ltd. has developed a test that measures the presence of dividing cells in a urine sample, where there should be no dividing cells, and thus is indicative of cancer. The start-up's lead indication is bladder cancer, but it is exploring its use in other cancers, including prostate.